|
Effect of multi-cancer early detection screening on late-stage cancers: A modeling study. |
|
|
Other Relationship - Value Analytics Labs (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Value Analytics Labs |
|
|
Employment - Exact Sciences |
Stock and Other Ownership Interests - Exact Sciences |
|
|
Employment - Exact Sciences |
Stock and Other Ownership Interests - Exact Sciences |
Travel, Accommodations, Expenses - Exact Sciences |
|
|
Stock and Other Ownership Interests - Illumina |
|
Consulting or Advisory Role - Exact Sciences; GRAIL; Verily |
|
|
No Relationships to Disclose |
|
|
Employment - Exact Sciences |
Stock and Other Ownership Interests - Exact Sciences |
|
|
Employment - Exact Sciences |
Leadership - Exact Sciences (Inst) |
Stock and Other Ownership Interests - Exact Sciences |
Consulting or Advisory Role - Exact Sciences (Inst) |
Research Funding - Exact Sciences (Inst); Ironwood Pharmaceuticals (Inst); Thorne Research (Inst) |
Patents, Royalties, Other Intellectual Property - Prior to becoming an Exact Sciences employee in July 2022, Dr. Limburg served as Chief Medical Officer for Screening at Exact Sciences through a contracted services agreement with Mayo Clinic. Dr. Limburg and Mayo Clinic had contractual rights to receive |
|
|
Employment - Exact Sciences |
Stock and Other Ownership Interests - Arvinas; Exact Sciences; Osheru; Osteologic; Salarius Pharmaceuticals |
Consulting or Advisory Role - Arvinas; Astellas Pharma; AstraZeneca; Bayer; GlaxoSmithKline; Sanofi |
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Freenome (Inst); GRAIL (Inst) |
|
|
Consulting or Advisory Role - Merck; Value Analytics Labs |
|
|
Leadership - Avalon Health Economics; Occam Research |
Stock and Other Ownership Interests - Avalon Health Economics; Occam Research |
Consulting or Advisory Role - Amgen; Bayer; Daiichi Sankyo; Exact Sciences; GlaxoSmithKline; Merck; Pfizer; Rhythm Biosciences; Roche; Takeda |